Literature DB >> 20803124

Imperatorin sustained-release tablets: In vitro and pharmacokinetic studies.

Jingjing Pan1, Wen Lu, Changhui Li, Sicen Wang, Langchong He.   

Abstract

We prepared and evaluated imperatorin (IMP) sustained-release tablets. IMP is an active compound in Angelica dahuricae, a Chinese herbal medicine. We used different polymers, such as hydroxypropyl methylcellulose (HPMC K4M, K15M, and K100M), carbopol 934P, sodium carboxymethyl cellulose (CMC-Na), and their combinations to prepare the matrix tablets and achieve the desired sustained release profile. The in vitro release profiles of these formulations were examined and fit to various kinetic release models. We also tested the effects of polymer combination ratios on the in vitro release rate. In vivo studies were performed for the optimized formulation in six beagle dogs, and pharmacokinetic parameters were compared with plain IMP tablets. IMP sustained-release tablets exhibited a more sustained plasma concentration than the plain tablets, with a relative bioavailability of 127.25%. The in vitro releases rates and in vivo absorption correlated for the initial 8 hours. These results demonstrate that the sustained-release tablet system can effectively control the release of IMP.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20803124     DOI: 10.1007/s12272-010-0811-3

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  2 in total

1.  Development of Paroxetine Hydrochloride Single Layer Controlled-Release Tablets Based on 3² Factorial Design.

Authors:  Yao Yang; Zhengwei Huang; Xuan Zhang; Jinyuan Li; Ying Huang; Wanxin Chen; Xin Pan; Chuanbin Wu
Journal:  Pharmaceutics       Date:  2018-11-20       Impact factor: 6.321

2.  Preparation, Characterization, and Pharmacokinetic Evaluation of Imperatorin Lipid Microspheres and Their Effect on the Proliferation of MDA-MB-231 Cells.

Authors:  Xinli Liang; Xulong Chen; Guowei Zhao; Tao Tang; Wei Dong; Chunyan Wang; Jing Zhang; Zhenggen Liao
Journal:  Pharmaceutics       Date:  2018-11-16       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.